Drug Profile
RG 6123
Alternative Names: RG6123; RO 7172508Latest Information Update: 02 Oct 2021
Price :
$50
*
At a glance
- Originator Roche
- Class Antineoplastics; Monoclonal antibodies
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Solid tumours
Most Recent Events
- 16 Oct 2019 Discontinued - Phase-I for Solid tumours (Late-stage disease, Metastatic disease) in Canada, Belgium, Spain, Denmark (SC) (Roche pipeline, October 2019)
- 16 Oct 2019 Discontinued - Phase-I for Solid tumours (Late-stage disease, Metastatic disease) in Denmark, Spain, Belgium, Canada (IV) (Roche pipeline, October 2019)
- 07 Aug 2019 Roche terminates a phase I trial in Solid tumours (Late-stage disease, Metastatic disease) in Canada, Belgium, Spain and Denmark due to lack of efficacy (SC) (IV) (NCT03539484)